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Statement of translational relevance 
Ovarian squamous cell carcinomas (SCC) arising in mature cystic teratomas (MCT) are rare 
malignancies of poor prognosis.  There are no published data on mutations in these tumors 
to guide future possible clinical trials.  Using archival samples from four large UK 
gynecologic cancer centers, we have performed next generation sequencing on 25 SCC 
samples with their associated MCT.  MCT had few copy number or single nucleotide 
variants.  SCC were all HPV negative, but had high mutation burden, with frequent 
abnormalities in TP53, PIK3CA and CDKN2A, at frequencies similar to lung SCC.  Strikingly, 
40% of the TP53 mutations were bi-allelic, which may be associated with improved outcome.  
This is the first genomic analysis of these rare tumours.  Our data suggest that patients with 
SCC arising in ovarian MCT could be included in any SCC-specific trial and may, like lung 
SCC, benefit from immune checkpoint inhibition.  
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Abstract 
Purpose 
We sought to identify the genomic abnormalities in squamous cell carcinomas (SCC) arising 
in ovarian mature cystic teratoma (MCT), a rare gynaecological malignancy of poor 
prognosis. 
 
Experimental design 
We performed copy number, mutational state and zygosity analysis of 151 genes in SCC 
arising in MCT (n=25) using next-generation sequencing. The presence of high/intermediate 
risk HPV genotypes was assessed by quantitative PCR.  Genomic events were correlated 
with clinical features and outcome 
 
Results 
MCT had a low mutation burden with a mean of only 1 mutation per case.  Zygosity analyses 
of MCT indicated four separate patterns, suggesting that MCT can arise from errors at 
various stages of oogenesis.  A total of 244 abnormalities were identified in 79 genes in 
MCT-associated SCC, and the overall mutational burden was high (mean 10.2 mutations per 
megabase).  No SCC was positive for HPV.  The most frequently altered genes in SCC were 
TP53 (20/25 cases, 80%), PIK3CA (13/25 cases, 52%) and CDKN2A (11/25 cases, 44%).  
Mutation in TP53 was associated with improved overall survival. In 8/20 cases with TP53 
mutations, two or more variants were identified, which were bi-allelic. 
 
Conclusions 
Ovarian SCC arising in MCT has a high mutational burden with TP53 mutation the most 
common abnormality.  The presence TP53 mutation is a good prognostic factor.  SCC 
arising in MCT share similar mutation profiles to other SCC.  Given their rarity, they should 
be included in basket studies that recruit patients with SCC of other organs. 
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Introduction 
Mature cystic teratoma (MCT) of the ovary (also known as dermoid cyst and benign cystic 
teratoma) is a common benign gynaecological tumour, usually arising before the menopause 
(1).  The origin of MCT remains uncertain.  Karyotype analyses suggested that there may be 
five separate types arising from different replication errors during meiosis (2) and that MCT 
may represent primary oocytes that have escaped from meiotic arrest (3).   
 
Because MCT contain all three germ cell layers, they often display multiple differentiated 
tissue types, including teeth, bone and hair.  However, secondary transformation into 
invasive malignancy can also occur, at reported rates of 0.1 - 1% (4, 5).  Up to 80% of these 
transformed teratomas contain squamous cell carcinoma (SCC), with the remaining 20% 
containing adenocarcinoma, thyroid carcinoma or carcinoid tumours (6). 
 
Due to their rarity, there are few large published series and no prospective clinical trials in 
MCT-derived SCC, and the recent Gynecologic Cancer Intergroup (GCIG) consensus review 
concluded that there were insufficient data to provide clear guidance on optimal treatment 
(7).  However, the prognosis for these SCC is poor, especially for stage II - IV disease 
[summarised in (6)].  As a consequence, there is a need to characterise the genomic 
features of these tumours, to identify opportunities for patients to enrol in clinical trials. 
 
Here we present analysis of the mutational state, copy number and zygosity of 151 cancer 
genes, as well as HPV status, in 25 cases of MCT with SCC from four large UK 
gynaecological cancer centres.   
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Patients and methods 
Study conduct, survival analyses and patient samples 
All samples were acquired and utilised under the auspices of the NHS Greater Glasgow and 
Clyde Biorepository following approval by West of Scotland Research Ethics Committee 4 
(Reference 10/S0704/60).  Overall survival was calculated from the date of diagnosis to the 
date of death or the last clinical assessment where known.  Overall survival was calculated 
by log-rank test (Mantel-Cox) using Prism v6.0 (GraphPad, San Diego, CA), whilst 
multivariate analysis was calculated using a Cox Proportional Hazard model in SPSS; 
p<0.05 was considered to be significant. 
 
Formalin-fixed paraffin-embedded specimens were identified from the pathology archives of 
participating centres.  Following review by an expert gynaecological pathologist, areas of 
squamous cell carcinoma (SCC), mature cystic teratoma (MCT) and normal tissue were 
marked for macro-or microdissection.  Laser capture microdissection (LCM) was performed 
on consecutive cresyl violet-stained sections using a Leica CTR6500 microscope (Leica 
Microsystems, Milton Keynes, UK). Sections were collected onto LCM-compatible 
polyethylene terephthalate (PET) frame slides (Leica Microsystems, Milton Keynes, UK). 
 
DNA extraction and quantification. 
DNA was extracted from 10 x 10 µm sections using QIAmp DNA FFPE Tissue Kit (Qiagen, 
UK) according to manufacturer’s protocol. For macrodissected samples, paraffin was 
removed by the xylene/ethanol method. For microdissected samples, paraffin was removed 
by the heptane method. Briefly, 500 µl heptane was added to the sample, followed by 10 
mins incubation at room temperature. 25 µl methanol was added, followed by centrifugation 
and aspiration. 1ml of absolute ethanol was then added to the pellet, followed by 
centrifugation and aspiration.  The pellet was then air dried. From here the standard QIAmp 
extraction method was followed as per manufacturer’s protocol. DNA was quantified on a 
Qubit 2.0 Fluorometer (Life Technologies, Paisley, UK). 
 
HPV Analysis 
High/intermediate risk HPV serotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) 
were assessed in 50ng SCC DNA using real-time PCR [HPV High Risk Taqman PCR Kit 
(Norgen BioTek, Thorold, ON, Canada)] using a CFX96 Touch Real-Time PCR System 
(BioRad, Watford, UK). 
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Sequencing and bioinformatic analyses 
50-200ng DNA was sheared with a Covaris LE220 focused-ultrasonicator (Covaris, Woburn, 
MA) to produce 100-200bp fragments.  Libraries were generated using SureSelect XT 
standard protocol (Agilent Technologies, Santa Clara, CA) for low-input and FFPE samples. 
Pre-capture libraries were quantified as above, then assessed for library size and impurities 
with a High Sensitivity DNA BioAnalyzer Chip (Agilent Technologies). Libraries were 
captured with 120nt biotinylated RNA baits designed for the ClearSeq Comprehensive 
Cancer Panel (Agilent Technologies), covering 151 cancer-associated genes (Table S1). 
Hybridization for capture libraries less than 3Mb was performed according to manufacturer’s 
protocol. Post-capture PCR incorporated primers with unique 8-bp indexes (Agilent 
Technologies) to facilitate multiplexing.  Final captured-libraries were quantified with a Qubit 
Fluorometer High Sensitivity DNA Assay (Invitrogen) and assessed for size distribution and 
quality on a High Sensitivity DNA BioAnalyzer Chip (Agilent Technologies). Pooled capture-
libraries were sequenced on a NextSeq 500 instrument (Illumina, San Diego, CA) or MiSeq 
instrument (Illumina) with 2 x 76-bp, paired-end reads according to manufacturer’s 
instructions.    
 
A full description of mapping, QC, point mutation and indel calling, copy number calling 
(Table S2) and zygosity analysis is provided in Supplementary Methods. 
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Results 
Patients and samples 
Thirty-one cases were originally identified.  Samples from three patients were missing.  
There were low DNA yields (<50ng) in two cases, and sequencing failed in one SCC case, 
leaving 77 samples from 25 cases that were successfully sequenced (Fig. 1; see Table S3 
for QC). Twenty cases had sample trios (normal, MCT, SCC; Table 1), five of which had two 
or more regions of SCC and one of which had two MCT samples. Four cases had normal-
SCC pairs and one case had MCT-SCC with no matching normal. In the sequenced cases, 
median age at diagnosis was 51.0 years (range 25 - 86) and 56% (14/25) had stage I 
disease (Table 1).   
 
Mutation and copy number analyses 
Figure 2 shows a summary of key mutation and copy number alterations in both SCC and 
MCT - full details are given in Tables S4 and S5.  MCT were genomically quiet, with few 
mutations per sample (median 0, mean 1, range 0 - 7), and only one sample showed high-
level copy number alterations – amplification of MYC and EGFR in SC025 (Fig. S1A), the 
latter of which was shared with the arising SCC. Two further MCT (SC006 and SC013) 
showed evidence of low-level copy number gains (Fig. S1B), while the remaining 18 had 
normal copy number profiles (Fig. S1C).  
  
SCC samples contained a median of 8 mutations per case (range 0 - 39), with an overall 
median mutational burden of 10.2 mutations per MB of sequenced DNA (range 0 - 49).  This 
is similar to that of lung SCC (8.4 per MB (8, 9)), and higher than head and neck SCC (3.2-
5.0/MB (10, 11)), but lower than skin SCC, which has one of the highest mutation rates of 
any malignancy (at least 50 mutations/MB (12)).  All cases were negative for 13 
high/intermediate risk HPV genotypes (Table S5).  
 
The most commonly altered genes were TP53 (20/25 cases, 80%) (Fig. 2B), including 4/20 
(20%) cases with mutations in codon 285 (p.E285L/Q), PIK3CA (13/25 cases, 52%) and 
CDKN2A, both by homozygous deletion (Table S6) and by point mutation (11/25 cases, 
44%), a pattern similar to lung (8) and skin SCC (12).  Many SCCs showed evidence of 
highly rearranged genomes, with multiple low-level gains and losses (Fig. S2A). 
Amplification of MYC was called in two cases (SC005, SC021) (Table S6) and gain of MYC, 
falling just below the threshold for amplification calling, was seen in a further three cases 
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(SC011, SC020, SC025), making the potential prevalence as high as 20% (5/25) (Fig. S2B). 
The only other recurrent amplification was JAK2 in two cases (SC020 and SC025) (Table 
S6). 
 
In five cases, there were two or more separate SCC samples. One of these (SC030) 
contained no detectable mutations, but in the remaining four cases, the TP53 mutation was 
an early and shared event, even in samples that showed some heterogeneity between 
samples (Table S6).  Two multi-sample cases (SC022, SC031) showed identical mutation 
profiles across samples, whilst the remaining two (SC014, SC025) showed some overlap: 
SC014 shared two mutations (TP53, GNAQ) with PIK3CA and CDKN2A changes in one 
sample only.  SC025 had four mutations in one sample and three in the second, but with 
only the TP53 variant being shared, and therefore the only one occurring prior to divergence 
of the two clones.  Where there were multiple mutations in one gene (e.g. DDX3X in SC022; 
APC in SC031), there was complete concordance between samples.  
 
TP53 mutations showed a striking pattern with 8/20 (40%) mutated cases containing two or 
more variants (Fig. 2A).  Several pieces of evidence suggested strongly that these 
abnormalities are bi-allelic rather than resulting from the presence of two or more discrete 
clonal populations or the existence of kataegis-like clusters.  Firstly, in SC006 the mutations 
were sufficiently close to be phased, but were not detected in the same sequencing read pair 
and thus must lie on separate alleles (Fig S3A). While the allele frequencies (18.4% and 
13.1%) and copy number state (neutral, log2 ratio shift of 0.05) do not preclude the possibility 
that these mutations are in separate clones, the heterogeneity analysis of the multi-region 
sampled SCCs shows that even where sub-clones are present, they share the same TP53 
mutation (Table S7). Secondly, high TP53 mutant allele frequencies in two cases can only 
be reconciled if the mutations are in the same cells. SC013 has TP53 mutation frequencies 
of 47.2% and 55.8%. If these mutations are in trans, they must account for 100% of TP53 
alleles and thus cannot be in separate cells unless those cells are either homozygously 
mutated (and therefore bi-allelic for the same mutation) or have loss of the second copy to 
remove all wild-type alleles. However, the copy number state for TP53 in SC013 is a log2 
ratio shift of -0.35, which, at most, would indicate single-copy loss of TP53 in a fraction of 
cells. The possibility that these mutations are in cis cannot be excluded here.  The same 
logic holds for SC021, which has TP53 mutation frequencies of 36.4% and 46.3% and a 
TP53 copy number log2 ratio shift of 0.11, indicating no copy number alteration.  Thirdly, two 
separate mutations were identified in SC005 at the same allele frequency at the same 
position (R280K at 21.4%, R280T at 22.9%), along with a third mutation (E285K) 14bp away 
that is in phase with the R280K mutation but always on a different allele to the R280T (Fig 
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S3). There is a fourth, splice region TP53 mutation in this case that was too far away to 
phase with the other mutations. The copy number state for TP53 in this case again indicated 
no copy number alteration (log2 ratio shift of 0.21).  Possible explanations are therefore that 
there are two identically sized subclones, one of which has either one or two TP53 mutations 
and the other has either two or three, depending on how the distant mutation phases 
(although it is important to note that the three subclone explanation is not possible in the 
absence of copy number alteration).  Alternatively, all TP53 mutations exist in the same cell 
with the splice mutation on the same allele as either the E285K/R280K or the R280T 
mutations. The only explanation common to all three of the scenarios described above is 
that the TP53 mutations in these cases are bi-allelic.  
 
There were other examples, albeit rare, of genes with multiple mutations, in a pattern 
consistent with an APOBEC signature (9). Two samples (SC001 and SC005) had more than 
two TP53 mutations, SC022 had three mutations in DDX3X, SC002 had three PIK3CA 
mutations and SC009 had four mutations in NOTCH1. These clusters of mutations were 
mainly C>T (12/19) and C>G (4/19) but, in a TpC context rather than the CpG context that 
would indicate the ubiquitous cytosine deamination signature.  However, numbers are small 
and sequencing of a larger genomic footprint would be required to capture enough mutations 
to carry out a formal signature analysis. 
 
The PIK3CA alterations were canonical activating mutations, with the two most frequent 
mutations (p.E545K and p.E542K) corresponding to the two most frequent hotspots in 
COSMIC (Catalogue of Somatic Mutations in Cancer).  CDKN2A was inactivated by a 
variety of mechanisms, the commonest being a large-scale deletion (8 cases), with 
nonsense mutation occurring in a single case and missense mutations in three cases. The 
missense mutations all occurred at mutation peaks in COSMIC, consistent with these events 
being under positive selective pressure and therefore inactivating.   
 
Other recurrent changes included mutation of SMARCA4 and KMT2A (4 cases each), gain 
of MYC (3 cases) and gain of JAK2 (2 cases). Driver point mutations, as opposed to 
structural changes, in KMT2A are relatively rare, as evidenced by its point mutation profile in 
COSMIC, which shows a very low level of mutation spread evenly across the whole length of 
the gene.  KMT2A has a relatively long coding sequence, making it more likely that 
mutations occur in it by chance. Given the size of our dataset we are unable to determine 
whether these KMT2A mutations are part of the so-called ‘long tail’ of driver mutations seen 
in many cancer types or if they represent the background mutation rate. The SMARCA4 
mutations are likely passengers as none of them matched the five most recurrent variants in 
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COSMIC. Mutations in BRCA1 and BRCA2 were identified in 2 cases each; all mutations 
were somatic missense alterations (Table S4). 
 
Clinical correlation 
Follow up data were available on 23 cases.  Twelve patients died and median overall 
survival was 20.1 months (Fig. 3A), with no deaths occurring more than 24 months following 
diagnosis.  The median follow-up for living patients was 55.8 months (range 6.8 – 172.6 
months) with 91% followed up for at least 41.6 months.  As previously described, survival 
was significantly better for stage I compared to stage II-IV disease (Fig. 3B; HR =  0.301; 
p=0.021).  There was no difference in survival based on age at diagnosis (Fig. 3C), PIK3CA 
or CDKN2A mutation status (Fig. S4A), but there was a statistically significant association 
with TP53 mutation (HR = 0.178; p=0.002; Fig. 3D).  Exploratory analysis suggested that 
cases with bi-allelic TP53 mutations had significantly better overall survival than those with 
mono-allelic mutations (HR = 0.140; p=0.029; Fig. S4B). The association of survival with 
stage and TP53 mutation status remained statistically significant (p=0.047 and p=0.011 
respectively) in multivariate analysis (Table 2). 
 
Zygosity analysis 
In order to determine the stage of oogenesis that gave rise to the MCT, we analysed SNPs 
in the 151 sequenced genes for heterozygosity, and for a change in zygosity between 
normal tissue and MCT.  All cases had some homozygous SNPs, but analysis of non-
homozygous SNPs revealed four groups (Table 3, Fig. S5).  Group A (10/21, 48%) showed 
the same levels of heterozygosity in normal and MCT, suggesting that they arise from cells 
prior to crossover (e.g. primordial germ cells or oogonia), whilst group B (3/21 cases, 14%) 
showed substantially fewer heterozygous positions in the MCT compared to normal.  This is 
consistent with development after prophase I in meiosis I, when chromosomal crossover 
occurs.  Group C (3/21,14%) had SNPs at the expected 0:1 and 0.5:0.5 ratios for diploid 
cells, but also had SNPs with other allelic ratios. SC011 and SC002, for example, showed 
SNPs at an allelic ratio of approximately 0.3:0.7. Given the absence of any copy number 
alterations in these samples, this would indicate a tetraploid MCT with some regions of the 
genome in a 2:2 maternal:paternal ratio and some in a 1:3 ratio.  SC013 showed an 
additional allelic ratio of approximately 0.2:0.8, consistent either with some regions being at 
6N in a 1:5 ratio between the maternal and paternal chromosomes or contamination of a 
group B-type profile with normal cells.  SC013 did show some regions of copy number 
change, making it difficult to eliminate this as an explanation of the altered SNP allele 
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frequencies.  However, in the other two MCTs with copy number alterations, there were 
insufficient SNPs within the limited regions of copy number change to impact on the peaks of 
SNP allele frequencies (Fig. S1B, Fig. S6, Table 3). Group D (6/21, 29%) did not have any 
SNPs in a 0.5:0.5 ratio but instead each showed a single allelic ratio consistent with a 
polyploid genome with unequal numbers of maternal and paternal chromosomes. For 
example, SC001, SC006 and SC030 all appeared to be pentaploid in a 2:3 ratio, while 
SC022, SC007 and SC029 were triploid (1:2 ratio), tetraploid (1:3 ratio) and hexaploid (1:5 
ratio) respectively.  
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Discussion 
We believe this to be the first description of the mutational landscape of squamous cell 
carcinoma (SCC) arising within mature cystic teratoma of the ovary (MCT, also known as 
dermoid cyst and benign cystic teratoma).  The data presented here show that MCT are 
genomically bland, but the associated SCC have a high mutation burden characterised by a 
high frequency of mutations in TP53, CDKN2A and PIK3CA.  TP53 mutation is an early 
event, and likely bi-allelic TP53 mutations are seen frequently.  Although previous individual 
case reports describe high risk HPV in an ovarian SCC (13), all 25 SCC analysed here were 
negative for high/intermediate risk HPV genomes.  There are few data on recurrent genomic 
abnormalities in malignant ovarian germ cell tumours (GCT) but SCC arising in MCT differ 
greatly from malignant testicular GCT, which have low mutational burden (0.9/MB) and are 
universally TP53 wild-type (14).  
 
Although we found mutations in genes frequently mutated in both lung and skin SCC (TP53 
and CDKN2A), these two tumour types also contain frequent mutations in NOTCH1, 2 and 3 
(15, 16).  We only identified NOTCH1 mutations in two of our 25 cases (8%), one of which 
had only a synonymous change.  However, our sequencing panel did not include other 
NOTCH genes.  The rates of both PIK3CA and CDKN2A abnormality in our samples are 
potentially higher than in lung and skin SCC, but, overall SCC arising in MCT has features in 
common with other non-HPV SCC.  A larger sample size would be required to make more 
definite statements about relative mutational frequency.  The overall mutational burden 
estimate for the SCC was high at 10.2 mutations per MB of sequenced DNA.  Assessment of 
mutation rates derived from cancer gene panels may over-estimate the genome-wide rate as 
these panels include only genes that are known to be under selective pressure.  Chalmers et 
al recently compared mutational burden estimates from whole exome sequencing with 
targeted panels, demonstrating close correlation between the two (10).  They also suggested 
that sequencing of approximately 1.1Mb of coding genome could accurately estimate overall 
mutational burden, with significant variance only below 0.5 Mb.  Our data were derived from 
approximately 0.8Mb, and thus may be an overestimate, but are largely in line for data from 
other SCC types, including NSCLC. 
 
Bi-allelic TP53 mutations have been identified in skin SCC (17).  Exome sequencing of eight 
skin SCC identified TP53 abnormalities in seven.  Four of these showed LOH at 
chromosome 17p, but the 3 remaining cases lacked LOH and contained two or more distinct 
TP53 mutations, presumed to be biallelic.  We are not aware of other descriptions of bi-
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allelic alterations in other SCC, nor of any previous potential correlation between bi-allelic 
TP53 mutations and improved outcome.   
 
There remains considerable debate as to the origin of MCT.  Originally thought to represent 
parthenogenic activation of oocytes (ie embryological development in the absence of a male 
gamete) at the end of meiosis I (18), cytogenetic analyses later suggested the existence of 
five separate MCT groups, arising from distinct stages of meiosis (2).  More recent short 
tandem repeat analyses generated conflicting data, supporting origins in oogonia (19) or 
primary oocytes that have escaped meiotic arrest (3).   
 
Our study was not designed to identify cell of origin of MCT, but to analyse whether there 
were obvious SCC precursor mutations present in MCT.  These we did not find - indeed, the 
MCT had few mutations or copy number alterations.  However, we did identify four separate 
zygosity states in the 22 MCT samples from 21 cases.  Groups A and B appear to have 
arisen primordial germ cells/oogonia and primary oocytes respectively.  Group C contained 
some SNPs with altered allelic ratios. In the absence any detectable copy number 
alterations, one potential mechanism for generating such a state would be fusion of a cell 
that has undergone meiosis I but not completed meiosis II with a somatic cell, such that 
regions that had crossed over would end up in a 1:3 ratio while the rest of the genome would 
be 2:2.  Alternatively this profile would be consistent with a mixture of a group B profile and 
contaminating normal cells. Group D, which lacked any SNPs in a 0.5:0.5 ratio but instead in 
each case showed a single allelic ratio consistent with a polyploid genome with unequal 
numbers of maternal and paternal chromosomes, may arise due to errors in meiosis I, when 
sets of homologous chromosomes should be separated. Given that only a single allelic ratio 
is present in these cells it seems unlikely that crossover has occurred.  
 
Analysis of any rare cancer is logistically problematic, and we acknowledge that there are 
potential shortcomings in our study.  Identifying rare cancer samples is challenging, and we 
acquired the original 31 samples only by interrogating the archives of four large UK 
gynaecological cancer centres, with limited clinical data available.  However, the clinical 
outcomes we describe are in line with a large systematic review (6), which suggests that our 
patients are broadly representative of this patient population.  SCC arising within MCT has 
the added disadvantage that it is almost invariably an unexpected pathological diagnosis in 
an apparently benign tumour - there are no proven imaging characteristics to differentiate a 
benign MCT from one containing SCC (20, 21).  We therefore had to work with archival 
formalin-fixed paraffin-embedded material up to 17 years old.  Finally, our sequencing panel, 
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although containing 151 genes, did not cover the whole exome, and so there may be critical 
mutations that we have missed.   
 
Despite these issues, this first systematic genomic evaluation of ovarian SCC arising in MCT 
shows clearly that they are similar to other non-HPV SCC, especially NSCLC, but with 
distinct features, including bi-allelic TP53 mutations.  Further studies will be required to 
address the question of MCT cell of origin and to understand what triggers transformation of 
the MCT into SCC.  However, our data suggest that patients with MCT-SCC could be 
included in trials of SCC-specific therapy and may, like lung SCC (22), derive benefit from 
immune checkpoint inhibition.  
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Tables 
Table 1 
Summary of patient characteristics and samples.  Stage is based upon FIGO classification at 
the time of diagnosis.  Samples: N, normal; M, Mature Cystic Teratoma; S, Squamous Cell 
Carcinoma. OS event: 0 = alive, 1 = dead.  NA - data not available 
 
Table 2 
Multivariate analysis of overall survival.  HR = Hazard Ratio; UL = Upper limit (95% 
confidence interval); LL = Lower limit (95% confidence interval) 
 
Table 3 
Zygosity summary of the MCT samples.  Columns 5 and 6 indicates the percentage of all 
SNPs that were heterozygote in MCT and normal tissue respectively for groups where the 
MCT showed the same set of frequency states as the normal ie 0. 0.5 and 1. For groups C 
and  D, the metric of percentage heterozygous SNPs is not relevant given the altered SNP 
frequencies in the MCT compared to the normal, and thus the analysis was not performed, 
as indicated by dashes (-). NA; sample not available 
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Figure legends 
Figure 1. Sample profile 
Flow of patients and samples in this study. 
 
Figure 2. Summary of genomic alterations 
A. Summary of frequently altered genes across the SCC and MCT samples (23, 24). Cases 
with bi-allelic TP53 mutation are marked *. 
B. Schematic representation of p53 showing protein domains. (Green, transactivation 
domain [TAD]; red, DNA binding domain [DBD]; blue, tetramerisation domain [TMD]) with 
lollipops showing positions and counts of identified mutations. Mutation type is indicated 
by circle fill: green, nonsynonymous; black, loss of function (including nonsense, splicing 
and frameshift); red, inframe indel/synonymous. 
 
Figure 3. Survival analyses 
A. Median overall survival for the whole cohort was 20.1 months 
B. Overall survival was significantly better for FIGO stage I compared to FIGO stage II-IV 
(HR 0.301; p=0.021) 
C. Age has no impact upon survival - overall survival by age at diagnosis (<median vs 
>median). 
D. Overall survival was significantly better for TP53 mutant cases compared to TP53 wild-
type cases (HR 0.178; p=0.002)  
 
Table 1
Study No
Age at 
Diagnosis 
(years)
Time since diagnosis 
(months) OS Event Stage Samples
SC001 78.0 44.5 0 IA N M S
SC002 60.0 13.4 1 IBB M S
SC005 35.0 NA NA IC2 N M S
SC006 43.5 55.5 0 IIIC N M S
SC007 53.6 55.8 0 IA N M S
SC008 51.0 64.6 0 IA N M S
SC009 61.0 123.8 0 IA N S
SC010 65.0 18.9 1 IIIC N M S
SC011 41.0 11.6 1 IIIB N M S
SC012 65.0 2.6 1 IIB N M S
SC013 58.0 20.1 1 IC2 N M S
SC014 29.0 24.2 1 IB N M Sx2
SC015 50.7 12.7 1 IIIC N M S
SC019 37.1 41.6 0 IA N M S
SC020 56.2 2.6 1 IC N M S
SC021 45.7 95.5 0 IA N M S
SC022 50.4 172.6 0 IA N M Sx2
SC023 31.3 83.3 0 IA N S
SC024 86.2 3.8 1 III N S
SC025 50.8 6.6 1 IIIC N M Sx2
SC027 68.0 42.1 0 II N S
SC028 46.0 NA NA III N M S
SC029 78.4 5.5 1 IC2 N M S
SC030 25.6 6.8 0 IA N M Sx3
SC031 73.1 7.2 1 IIA N Mx2 Sx2
Table 2
Variable Category N (events) HR LL UL P-value
TP53 WT (ref) 4 (3) 1 - - 0.011
Mono 12 (8) 0.015 0.001 0.253
BI 7 (1) 0.077 0.01 0.602
Stage I (ref) 13 (4) 1 - - 0.047
II-IV 10 (8) 3.802 1.017 14.285
Table 3
Group Study No. Non-homozygous allele frequency (MCT)
Non-homozygous allele 
frequency (Normal)
Heterozygous 
SNPs MCT (%)
Heterozygous 
SNPs Normal (%) Copy Number profile
A SC005 0.5 0.5 39.9 39.9
A SC010 0.5 NA 39.4 NA
A SC012 0.5 0.5 38.6 38.6
A SC015 0.5 0.5 34.0 38.0
A SC020 0.5 0.5 43.5 43.3
A SC021 0.5 0.5 33.6 33.6
A SC025 0.5 0.5 30.4 29.6 Amplification of MYC and EGFR
A SC028 0.5 0.5 33.4 33.4
A SC031_MCT1 0.5 0.5 31.1 31.1
A SC031_MCT2 0.5 0.5 31.1 31.1
B SC008 0.5 0.5 23.6 41.9
B SC014 0.5 0.5 18.9 37.5
B SC019 0.5 0.5 17.6 36.1
C SC002 0.3; 0.5; 0.7 NA - NA
C SC011 0.3; 0.5; 0.7 0.5 - 43.7
C SC013 0.2; 0.5; 0.8 NA - NA Some low-level changes
D SC001 0.4; 0.6 0.4; 0.6 - -
D SC006 0.4; 0.6 0.5 - 37.1 One low-level gain
D SC007 0.25; 0.75 0.5 - 41.1
D SC022 0.3; 0.7 0.5 - 38.4
D SC029 0.2; 0.8 0.5 - 38.4
D SC030 0.4; 0.6 0.5 - 36.1
PATIENTS
31 identified
Missing samples
3 samples in 3 patients
GENOMIC ANALYSES
20 SCC-MCT-normal
4 SCC-normal
1 SCC-MCT
SEQUENCING
26 patients
DNA EXTRACTION
28 patients
Sequencing failure
1 SCC in 1 patient
<50ng DNA yield
7 samples in 2 patients
Pass QC
77 samples 25 patients
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